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CLINICAL STUDY
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ABSTRACT
Objectives: The successful implantation of peritoneal dialysis (PD) catheters is a critical skill pro-
cedure with the potential to impact both the short- and long-term success of renal replacement
therapy and the patients’ survival.
Methods: We retrospectively reviewed our single-center experience with nephrologist-placed
minimally invasive, double-cuffed PD catheters (PDCs).
Results: The recruitment period was March 2014 through December 2015. The follow-up period
lasted until 2016. The mean age of the subjects was 60±18 years and indications for the PD
were diuretic resistant acutely decompensated chronic heart failure in seven patients (47%) and
end-stage renal disease in eight (53%) patients. Comorbid conditions included diabetes (27%),
ischemic heart disease (47%), advanced liver failure (27%), and a history of hypertension (73%).
The cohort had a high mortality with five subjects only in severe heart failure group (33%) pass-
ing away during the index hospitalization; of the rest, two (13%) had heart transplantation, three
(20%) changed modality to hemodialysis, and only five (33%) continued with maintenance PD
beyond 1 month. Acute technical complications within the first month were infrequent: one
catheter (6%) had drainage problems and one (6%) was lost due to extrusion. There were no ser-
ious complications (e.g., organ damage, peritonitis, etc.).
Conclusions: In selected cases, particularly in severe diuretic refractory heart failure, PDC place-
ment placed by a nephrologist is feasible with a low rate of complications even in a low-volume
center setting. The catheters we placed were all functioning with only minor complications and
PD could be started immediately.
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Introduction
Indications and techniques for peritoneal dialysis (PD)
as well as the practice of modality will continue to
evolve, influenced to a large degree by local needs and
the availability of expertise and skills. In Hungary, the
modality took root in 1960 [1], with the initial rigid
straight catheters gradually replaced by the Tenckhoff
catheters in subsequent years [2]. While historically, PD
catheters (PDCs) were inserted by surgeons, the need
soon became apparent for a simplified procedure utiliz-
ing local anesthesia and performed outside of the oper-
ating rooms. The fluoroscopic insertion of PDC by
nephrologists using the Seldinger technique can be
performed in a procedure room, allowing the exped-
itious initiation of dialysis without involving a surgical
team [3]. Those non-surgically inserted PDCs were and
still are sutured to the rectus muscle or fascia [4]. Early
clinical results confirmed the functional equivalency of
non-surgically implanted PDCs to surgically placed
ones, also proving to be reliable as long-term PD access
[5]. For proper wound healing, a minimum of 4–6-
week-long waiting period is needed after PDC place-
ment before starting regular PD with full PD fluid
exchange. Further comparative clinical studies had
shown that PDC placement is safe even during bedside
catheter insertion, particularly for patients with poor
cardiac function; it proves to be equally safe when man-
aging secure anesthesia, when endotracheal intubation
is impossible, or the surgeon is not comfortable with
the procedure in local anesthesia [6–10]. The advantage
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of minimally invasive catheter insertions is less surgical
trauma permitting an earlier start on PD fluid exchange
without any waiting period [11–13]. Non-surgical place-
ment is preferable for cases requiring an urgent initi-
ation of dialysis [14]. Long-term retrospective clinical
studies had clearly demonstrated the benefits of minim-
ally invasive interventions [15–18] and may offer a
viable alternative in resource-limited countries or when
the risks of true surgical procedures impede the estab-
lishment of modality.
Materials and methods
This is a retrospective study approved by the Ethics
Committee of the Hungarian Health Ministry (equiva-
lent for an Independent Review Board) (TUKEB 28962-3/
2018/EKU) and the Fresenius Medical Care as the local
dialysis provider in Hungary. The study conforms to the
Helsinki Declaration as developed by the World Medical
Association. All patients provided written informed con-
sents for the procedure.
The PDC insertion was utilized initially for those with
a severe diuretic-resistant acute decompensated heart
failure and cardio-renal syndrome; subsequently, it was
expanded to other patients with end-stage renal dis-
ease opting for upstart PD. In those patients with
severe diuretic-resistant heart failure, the surgical place-
ment was contraindicated, or the surgeon was not will-
ing to place the catheter; the patient had severe
hypotension and needed circulation support with medi-
cation, or the anesthesiologist contraindicated any sur-
gically interventions. Most of patients with ESKD were
without prior regularly nephrology care and had eGFR
<10mL/min/1.73 m2 but without any sign of uremia, or
severe acidosis or high level of potassium. We enrolled
those patients with ESKD from our nephrology unit
who had to start renal replacement therapy but had no
emergencies.
We modified the previously described PDC insertion
and reported our method in details before [19]. Briefly,
the insertion point for PDC was the left lower quadrant
for subsequent intraabdominal placements of the cath-
eter. In our experience, this approach showed the most
efficient learning curve for operators, especially in the
presence of peritoneal ascites fluid accumulation. We
believe this insertion point is much safer, than other
insertion points described earlier. We made only a
20mm length incision to the skin for introducing the
catheter. The ascites drainage by physician is a rou-
tinely intervention. Moreover, nephrologists place tun-
neled hemodialysis (HD) catheters routinely, too. The
PDC placement was carried out applying a sterile
technique and fluoroscopy was used to visualize the
advancement of the guidewire. In order to avoid any
complications, e.g., injury of abdominal organs, we later
used the Veress needle, which is a spring-loaded needle
used to create pneumoperitoneum for laparoscopic sur-
gery. Of all the general approaches to laparoscopic
access, this technique is the oldest one dating back to
1932 [20]. All patients received prophylactic antibiotics
and the procedures were carried out under local anes-
thesia with 1% lidocaine without epinephrine. We uti-
lized the straight silicone Tenckhoff catheter with two
Dacron rings manufactured by Fresenius Medical Care
GmbH (Bad Homburg, Germany) in all cases. The PDC
was introduced into the peritoneal cavity with the
assistance of the COVIDIEN ArgyleTM 16 Fr Chronic
Catheter Accessory Set (Medtronic, Minneapolis, MN).
After we had introduced the catheter, we removed ‘the
peel away sheet’. The exit site and the tunnel were
made using blunt dissection with a hemostat and cre-
ated a catheter’s curve in the tunnel. The subcutaneous
cuff was placed 2 cm from the skin exit. The Tenckhoff
catheter was connected to the dialysis tubing at the
end of the procedure, and we checked the drainage
with 500mL dialysis solution.
All patients were started on PD immediately after
PDC insertion with a Fresenius Medical Care Stay-safe
Balance 1.5% dextrose-based solution (2000mL,
1.25mmol/L calcium, 134mmol/L sodium, 0.5mmol/L
magnesium, 102.5mmol/L chloride, 35mmol/L sodium
acetate, and 83.2mmol/L glucose). We started the PD
solution exchange two or three times a day in patients
with severe heart failure, and the intraperitoneal vol-
ume was 2000mL. The equilibration time was typically
4 or 6 h, depending on the exchange frequency. The
basic PD exchange prescription for ESRD’s patients was
four exchanges with 2000mL volume, and 6 h dwell
time. All patients were treated with CAPD; we did not
use APD, or any other automated equipment. Every
PDC insertion was made for hospitalized patients and
patients spent at least five days in the hospital after the
PDC insertion and initiation of the PD solution
exchanges, mostly because of their comorbidities.
Results
The recruitment period for the procedure was from
March 2014 through December 2015 during which time
15 subjects received the described long-term PDC
access. The follow-up period lasted until 2016, and
patient’s data were collected in 2018.
The patients’ demographic data and major co-
morbid conditions are described in Table 1. Their average
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age was 60 (±18) years; 87% were men and 27% dia-
betic. Almost half of them (47%; seven of 15) received
their PDC for severe diuretic resistant acutely decom-
pensated chronic heart failure and eight (53%) for end-
stage kidney disease (ESKD) without heart failure. To be
noted, however, a significant part of our cohort (27%)
had advanced liver disease. At the end of the clinical
follow-up, only three out of the 15 (20%) patients were
transferred to HD. We transferred those three patients
into HD 1 year after the PDC insertion due to severe
peritonitis or ineffective PD treatment. We lost five
patients (33%) due to end-stage heart failure, while two
(13%) underwent successful cadaveric heart transplant-
ation subsequently (Table 2). Of those five patients four
died 16 months after the PDC insertion because of the
complications of the end stage heart failure, and one
patient died 1 month after PDC insertion due to acute
gastrointestinal bleeding. Most of patients in the severe
diuretic-resistant heart failure group had ascites. We
observed in those patients that the ascites volume had
decreased during PD treatment. Anecdotal observations
from the survivor cohort suggested a much-decreased
rate of repeated hospitalizations with heart failure
decompensation in the cardio-renal patients [21]. No
serious complications, such as injury to abdominal
organs, severe bleeding or infections were observed in
any of the cases. There was one patient whose initial
PD placement failed due to surgical abdominal adhe-
sions and needed surgical PDC placement. We observed
catheter sliding in three of the 15 (20%) patients only.
The slipping out occurred on the average one and a
half month after the PDC insertion and were thought to
be patient behavior-related. One patient lost his PDC
due to catheter extrusion and suture dehiscence. We
think there is no connection between the catheter lost
and PDC insertion, catheter extrusion can occur after
surgical insertion, too. We did not observe any early
infectious complications; two (13%) patients had late
PD-associated peritonitis (Table 3), which had no correl-
ation with PDC insertion. Despite an ‘early’ start on
dialysis, i.e., immediately after PDC placement, we expe-
rienced PD solution leakage neither during early, nor
subsequent follow-ups.
Discussion
PDC insertion is primarily performed by surgeons in
many medical cultures, including Hungary. The percu-
taneous blind technique and also the above-described
fluoroscopic technique are minimally invasive proce-
dures with decreased surgical risks and the potential for
an earlier initiation of an effective PD modality. In our
series, an early initiation of renal replacement therapy
not only afforded early volume and uremic control, but
also prevented large volume ascites accumulation in
those with co-morbid advanced heart failure or cirrho-
sis. Therefore, and only seemingly ‘paradoxically’, initiat-
ing the procedure may have contributed to the lack of
abdominal fluid leakage in our patients with advanced
heart failure and liver cirrhosis. Moreover, PD is an
unusual modality, where the efficacy of the procedure
is partially disconnected from small solute clearance
due to the predominant generation of uremic toxins in
the abdominal compartment [22]. The traditional surgi-
cal implantation still has its niche when abdominal
adhesions are present or when the patient’s excess
weight does not permit a safe procedure [23].
The above-described cohort represented the evolu-
tion of indications in our center explored initially for
those with severe acute decompensated diuretic resist-
ant heart failure [21] and addressing an unmet need for
effective volume control. In this patient group, the time
spent on PD treatment was an average of 10.8 months
and the cause of death remained unrelated to PD. The
Table 2. Outcome for patients having undergone percutan-
eous PD catheter insertion.
Patient outcome n: 15
Died 5 (33%)
Modality change PD/HD 3 (20%)
Heart transplant 2 (13%)
PD ongoing 5 (33%)
Table 3. Technical outcomes and complications.
Complications (n: 15) 1 month 1 month
Leakage 0 (0%) 0 (0%)
Catheter loss 1 (6%) 3 (20%)
Drainage disorder 1 (6%) 0 (0%)
Exit site infection 0 (0%) 0 (0%)
Peritonitis 0 (0%) 2 (13%)
Bleeding 0 (0%) 0 (0%)
Injury to abdominal organs 0 (0%) 0 (0%)
Death 0 (0%) 5 (33%)
Table 1. Demographic data of patients undergoing nephrolo-
gist-placed PD catheter insertion.
Demographic data n: 15
Male 13 (87%)
Female 2 (13%)
Age (years) 60 (±18)
Peritoneal dialysis indication
Heart failure 7 (47%)
End-stage kidney disease 8 (53%)
Comorbid conditions
Diabetes mellitus 4 (27%)
Hypertension 11 (73%)
Ischemic heart disease 7 (47%)
Liver disease 4 (27%)
436 A. PETH}O ET AL.
patients with severe heart failure have a high rate of
mortality. The patients in our series were deemed not
to be candidates for surgical PDC placement and, not
being candidates for cardiac transplantation at that
time, only comfort measures could have been offered
for them. Our experience herewith and in parts pub-
lished before [21] suggests that this technique can be
performed successfully even in a resource-limited envir-
onment and in a low volume setting. Moreover, our ser-
ies demonstrates success in patients with large degrees
of comorbid disease burden and an opportunity to
enhance both survival and quality of life.
Notwithstanding our positive results, PDC insertion
should be performed in medical centers only with both
expertise in PD and appropriate surgical background to
address procedure-related complications. We believe
nephrologist who are familiar with tunneled HD central
vein catheter insertion, will able to gain expertise in the
PDC technique. For learning a successful technique,
however, and minimizing complications with the PDC
insertion a formal training at a dedicated center is
necessary. We are confident that the modified PDC
insertion technique is easier when using the typical
abdominal paracentesis entry point. Due to the punc-
ture of the peritoneum and minimizing the incision to
the skin, we were able to start PD immediately without
waiting for proper wound healing of 6–8 weeks.
Notwithstanding, we were using acute PD where imme-
diate catheter use was required.
Peritoneal ultrafiltration can be a therapeutic strat-
egy for patients with severe congestive heart failure
(CHF). Peritoneal ultrafiltration is a relatively simple
choice for chronic salt and water removal and may be
beneficial for the management of patients with CHF
who develop severe edema, who are frequently admit-
ted to the hospital and have a much-reduced cardiac
reserve [24]. To be noted, we observed the same
decreased rate of rehospitalizations in our severe diur-
etic-resistant heart failure group. During the follow-up
period with CAPD in our patients with diuretic-resistant
heart failure, we noted an improved quality of life. The
readmission rate to hospital dramatically decreased
after the start of PD [21]. Thus, of the five patients four
died 16 months after the PDC insertion because of
complications of end stage heart failure, all patients
had superior improvement in quality of life due to PD.
We observed that PD-related improvement in left ven-
tricular ejection fraction (LEVF) was associated with bet-
ter quality of life and reduced hospitalization. Renal
dysfunction is prevalent in patients with severe heart
failure, and it is an established independent prognostic
factor in those patients. Nevertheless, the degree of
renal dysfunction did not affect the survival rate,
although PD-related improvement in LEVF was associ-
ated with better survival [25]. In selected cases, the
acute placement of PDCs may be appropriate even in
correlation with liver cirrhosis or complex hepato-car-
dio-renal pathophysiology.
Of note, two of our acutely decompensated chronic
heart failure patients received successful orthotopic
heart transplants. Our series is the first in Hungary to
document acute PD treatment in lieu of HD to address
diuretic resistant CHF, while also enabling subsequent
successful heart transplantation for some of our
patients [26]. In our clinical experiment, we were able
to treat patients successfully with CAPD in severe
chronic heart failure. Our patients on CAPD have been
stable and got compensated heart functions. Moreover,
our patients with heart failure had improved quality of
life till successful orthotopic heart transplantation.
Patients with severe diuretics resistant CHF, who require
mechanical circulatory support have much higher rates
of morbidity and mortality from infections attributable
to temporary blood stream access and extracorporeal
circulation devices. Accordingly, PD probably should be
considered in patients who require renal replacement
therapy [27].
Conclusions
The acute placement of PDC for urgent-start PD can be
effectively performed even in a resource-limited envir-
onment of a low-volume clinical program. Our results
offer a model for minimally invasive, cost-effective inte-
grated care in regional medical centers. The results of
our cohort should be interpreted with due consider-
ation of its limitations, limited number of patients
undergone PDC insertion, lack of a matched control
group, and short period of time during which patients
were followed. However, the importance of our investi-
gation is that we could start the PD immediately with
modified PDC insertion instead of waiting for 6–8 weeks
customary for PDC for chronic use.
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